Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jun 19;115(25):E5640-E5641.
doi: 10.1073/pnas.1804781115. Epub 2018 Jun 7.

Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change

Demetrios G Vavvas  1 , Kent W Small  2 , Carl Awh  3 , Brent W Zanke  4 , Robert J Tibshirani  5   6 , Rafal Kustra  7
Affiliations
Comment

Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change

Demetrios G Vavvas et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: B.W.Z. is an officer of ArcticDx, which holds patents relevant to results. C.A. and R.K. are technical consultants of ArcticDx.

Figures

Fig. 1.
Fig. 1.
Cox proportional hazard estimate of the proportion of GTG2 individuals remaining free of GA or neovascular disease (Left) or just neovascular disease (Right) using the 535-patient validation set of Assel et al. (7). New patient data provided by the NIH in conjunction with the work by Assel et al. (7), which underscores the distinction between GA and choroidal neovascularization (CNV) as distinct progression phenotypes, validate previous observations. The GA endpoint is not relevant for AREDS prophylaxis and should be removed from the statistical analyses. Some patients benefit (GTG3), and some may be harmed (GTG2). Reproduced with permission from ref. .
See this image and copyright information in PMC

Comment on

References

    1. Vickers AJ. Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration. Proc Natl Acad Sci USA. 2018;115:E5639. - PMC - PubMed
    1. Vavvas DG, et al. CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. Proc Natl Acad Sci USA. 2018;115:E696–E704. - PMC - PubMed
    1. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436. - PMC - PubMed
    1. Seddon JM, Silver RE, Rosner B. Response to AREDS supplements according to genetic factors: Survival analysis approach using the eye as the unit of analysis. Br J Ophthalmol. 2016;100:1731–1737. - PMC - PubMed
    1. Awh CC, Hawken S, Zanke BW. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology. 2015;122:162–169. - PubMed

Substances

LinkOut - more resources